Abstract
Aim:
In light of the antinociceptive activity of the short-chain neurotoxin, cobrotoxin, and other acetylcholine antagonists, the antinociceptive activity and mechanisms of cobratoxin (CTX), a long-chain postsynaptic α-neurotoxin, was investigated in rodent pain models.
Methods:
CTX was administered intraperitoneally (30, 45, 68 μg/kg), intra-cerebral ventricularly (4.5 μg/kg) or microinjected into periaqueductal gray (PAG; 4.5 μg/kg). The antinociceptive action was tested using the hot-plate and acetic acid writhing tests in mice and rats. The involvement of the cholinergic system and opioid system in CTX-induced analgesia was examined by pretreatment of animals with atropine (0.5 mg/kg, im; or 10 mg/kg, ip) or naloxone (1 and 5 mg/kg, ip). The effect of CTX on motor activity was tested using the Animex test.
Results:
CTX exhibited a dose-dependent analgesic action in mice as determined by both the hot-plate and acetic acid writhing tests. The peak effect of analgesia was seen 3 h after administration. In the mouse acetic acid writhing test, the intra-cerebral ventricular administration of CTX at 4.5 μg/kg (1/12th of a systemic dose)produced marked analgesic effects. Microinjection of CTX (4.5 μg/kg) into the PAG region did not elicit an analgesic action in rats in the hot-plate test. Atropine at 0.5 mg/kg (im) and naloxone at 1 and 5 mg/kg (ip) both failed to block the analgesic effects of CTX, but atropine at 10 mg/kg (ip) did antagonize the analgesia mediated by CTX in the mouse acetic acid writhing test. Acetylsalicylic acid (300 mg/kg) did not enhance the analgesic effects of CTX. At the highest effective dose of 68 μg/kg the neurotoxin did not change the spontaneous mobility of mice.
Conclusion:
CTX has analgesic effects, which are mediated in the central nervous system though not through the PAG. The central cholinergic system but not opioid system appears to be involved in the antinociceptive action of CTX.
Similar content being viewed by others
Article PDF
References
Yang CC . Cobrotoxin: structure and function. J Nat Toxins 1999; 8: 221–33.
Grasset E . The cobra neurotoxin; pharmacology and clinical applications in the treatment of pain. Med Hyg (Geneve) 1952; 10: 55–8.
Chen R, Robinson SE . Effect of cholinergic manipulations on the analgesic response to cobrotoxin in mice. Life Sci 1990; 47: 1949–54.
Shiraishi M, Minami K, Uezono Y, Yanagihara N, Shigematsu A, Shibuya I . Inhibitory effects of Tramadol on nicotinic acetyl-choline receptors in adrenal chromaffin cells and in Xenopus oocytes expressing alpha7 receptors. Br J Pharmacol 2002; 136: 207–16.
Irnaten M, Wang J, Venkatesan P, Evans CK, Chang KS, Andresen MC, et al. Ketamine inhibits presynaptic and postsynaptic nicotinic excitation of identified cardiac parasympathetic neurons in nucleus ambiguus. Anesthesiology 2002; 96: 667–74.
Lukas RJ . Diversity and patterns of regulation of nicotinic receptor subtypes. Ann NY Acad Sci 1955; 757: 153–8.
Servent D, Anti-Delbeke S, Gaillard C, Corringer PJ, Changeux JP, Menenz A . Molecular characterization of the specificity of interactions of various neurotoxins on two distinct nicotinic acetylcholine receptors. Eur J Pharmacol 2000; 393: 197–204.
Dajas-Bailador F, Costa G, Dajas F, Emmett S . Effects of α-bungarotoxin, α-cobratoxin and fasciculin on the nicotine-evoked release of dopamine in the rat striatum in vivo. Neurochem Intl 1998; 33: 307–12.
Lena C, Changeux JP . Role of Ca2+ ions in nicotinic facilitation of GABA release in mouse thalamus. J Neurosci 1997; 17: 576–85.
Pu XC, Wong PT, Gopalakrishnakone P . A novel analgesic toxin (hannalgesin) from the venom of king cobra (Ophiophagus hannah). Toxicon 1995; 33: 1425–31.
Adriana CM, Andreimar MS, Silvia HAE, Vitor MF, Lewis G, Sergio Z, et al. The analgesic activity of crotamine, a neurotoxin from Crotalus durissus terrificus (South American rattlesnake) venom: a biochemical and pharmacological study. Toxicon 1998; 36: 1927–37.
Rudd CJ, Viskatis LJ, Vidal JC, Etcheverry MA . In vitro comparison of cytotoxic effects of crotoxin against three human tumors and normal human epidermal keratinocyte cell line. In vest New Drugs 1994; 12: 183–4.
Corin RE, Viskatis LJ, Vidal JC, Etcheverry MA . Cytotoxicity of Crotoxin on murine erythroleukemia cells in vitro. Invest New Drugs 1993; 11: 11–5.
Cura JE, Blanzaco DP, Brisson C, Cura MA, Cabrol R, Larrateguy L, et al. Phase I and pharmacokinetics study of crotoxin (cytotoxin PLA2, NSC-624244) in patients with advanced cancer. Clin Cancer Res 2002; 8: 1033–41.
Pedigo NW, Dewey Wl, Harris LS . Determination and characterization of the antinociceptive activity of intraventricularly administered acetylcholine in mice. J Pharmacol Exp Ther 1975; 193: 845–52.
Paxinos G, Watson C . The rat brain in stereotaxic coordinates. 2nd ed. New York: Academic Press; 1986.
Yaksh TL, Yeung JC, Rudy TA . Systematic examination in the rat of brain sites sensitive to the direct application effects with the periaqueductal gray. Brain Res 1976; 114: 1183–8.
Karlsson E . Chemistry of protein toxins in snake venoms. In: Lee CY, editor. Handbook of experimental pharmacology. New York: Springer-Verlag; 1979. p 159–83.
Jensen TS, Yaksh TL . Comparison of antinococeptive action of morphine in the periaqueductal gray, medial and puramedial medulla in rat. Brain Res 1986; 363: 99–113.
Harris LS, Dewey WL . Role of cholinergic systems in the central action of narcotic agonists and antagonists. In: Kosterlitz HW, Collier HOJ, Villareal JE Agonist and antagonist actions of narcotic analgesic drugs. London: Macmillan 1972. p 198–206.
Xiong Y, Wand W, Pu X, Song J . Preliminary study on the mechanism of using snake venoms to substitute for morphine. Toxicon 1992; 30: 567.
Tseng LF, Chiu TH, Lee CY . Absorption and distribution of I-labeled cobra venom and its purified toxins. Toxicol Appl Pharmacol 1968; 12: 526–35.
Decker MW, Meyer MD, Sullivan JP . The therapeutic potential of nicotinic acetylcholine receptor agonists for pain control. Expert Opin Investig Drugs 2001; 10: 1819–30.
Damaj MI, Meyer EM, Martin BR . The antinociceptive effects of alpha7 nicotinic agonists in an acute pain model. Neurophar-macology 2000; 39: 2785–91.
Mundy HR, Jones SJ, Hobart JC, Hanna MG, Lee PJ . A randomized controlled study of modified cobratoxin in adrenomyelo-neuropathy. Neurology 2003; 61: 528–30.
Smith MT, Cabot PJ, Ross FB, Robertson AD, Lewis RJ . The novel N-type calcium channel blocker, AM336, produces potent dose-dependent antinociception after intrathecal dosing in rats and inhibits substance P release in rat spinal cord slices. Pain 2002; 96: 119–27.
Author information
Authors and Affiliations
Corresponding author
Additional information
Project supported by an initiative fund from Soochow University, Suzhou, China and by Recepto Pharm, USA.
Rights and permissions
About this article
Cite this article
Chen, Zx., Zhang, Hl., Gu, Zl. et al. A long-form α-neurotoxin from cobra venom produces potent opioid-independent analgesia. Acta Pharmacol Sin 27, 402–408 (2006). https://doi.org/10.1111/j.1745-7254.2006.00293.x
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1111/j.1745-7254.2006.00293.x
Keywords
This article is cited by
-
Cobrotoxin could be an effective therapeutic for COVID-19
Acta Pharmacologica Sinica (2020)
-
Purification and characterization of a novel antinociceptive peptide from venom of Agkistrodon halys Pallas
Archives of Pharmacal Research (2013)
-
Involvement of cholinergic system in suppression of formalin-induced inflammatory pain by cobratoxin
Acta Pharmacologica Sinica (2011)
-
Hyperalgesic and edematogenic effects of peptides isolated from the venoms of honeybee (Apis mellifera) and neotropical social wasps (Polybia paulista and Protonectarina sylveirae)
Amino Acids (2011)
-
Hypothesis of snake and insect venoms against Human Immunodeficiency Virus: a review
AIDS Research and Therapy (2009)